Current Report Filing (8-k)
March 27 2020 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 27, 2020
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
000-23661
|
38-3317208
|
(State or other jurisdiction
of incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
411 Hackensack Avenue, Suite 501,
Hackensack, New Jersey 07601
(Address of principal executive offices,
including zip code)
(248) 960-9009
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each exchange on which
registered
|
Common Stock, par
value $0.0001
|
|
RMTI
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
On
March 27, 2020, Rockwell Medical, Inc. issued a press release announcing that the U.S. Food and Drug Administration approved
Triferic® AVNU (ferric pyrophosphate citrate), its intravenous formulation of Triferic for replacement of iron and maintenance
of hemoglobin in hemodialysis patients. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Item
9.01
|
Financial Statements
and Exhibits.
|
(d) Exhibits.
|
The following exhibit is being furnished herewith:
|
EXHIBIT INDEX
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ROCKWELL MEDICAL, INC.
|
|
|
|
Date: March 27, 2020
|
By:
|
/s/ Stuart Paul
|
|
|
Stuart Paul
|
|
|
Chief Executive Officer
|
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024